HIF-1α confers aggressive malignant traits on human tumor cells independent of its canonical transcriptional function

Cancer Research

Volumn 71, Issue 4, 2011, Pages 1244-1252

  Yoo, Young Gun ^a   Christensen, Jared ^a   Huang, L Eric ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INVASION; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; HUMAN CELL; HYPOXIA; MALE; MALIGNANT NEOPLASTIC DISEASE; MALIGNANT TRANSFORMATION; MOUSE; MUTATION; NONHUMAN; ONCOGENE C MYC; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR CELL; TUMOR GROWTH;

ANIMALS; ARYL HYDROCARBON RECEPTOR NUCLEAR TRANSLOCATOR; CELL ADHESION; CELL HYPOXIA; DISEASE PROGRESSION; GENES, MYC; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MALE; MICE; MICE, NUDE; NEOPLASM INVASIVENESS; NEOPLASMS; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 79951820679     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-10-2360     Document Type: Article

References (50)

1. Brown JM. Exploiting the hypoxic cancer cell: mechanisms and therapeutic strategies. Mol Med Today 2000;6:157-62. (Pubitemid 30171366)
2. 2 availability on human cancer. Nat Rev Cancer 2008;8:967-75.
3. Giaccia A, Siim BG, Johnson RS. HIF-1 as a target for drug development. Nat Rev Drug Discov 2003;2:803-11. (Pubitemid 37361812)
4. 2 tension. Proc Natl Acad Sci U S A 1995;92:5510-4.
5. Tian H, McKnight SL, Russell DW. Endothelial PAS domain protein 1 (EPAS1), a transcription factor selectively expressed in endothelial cells. Genes Dev 1997;11:72-82. (Pubitemid 27043825)
6. Huang LE, Bunn HF. Hypoxia-inducible factor and its biomedical relevance. J Biol Chem 2003;278:19575-8. (Pubitemid 36799137)
7. 2-dependent degradation domain via the ubiquitin-proteasome pathway. Proc Natl Acad Sci U S A 1998;95:7987-92.
8. Kallio PJ, Wilson WJ, O'Brien S, Makino Y, Poellinger L. Regulation of the hypoxia-inducible transcription factor 1alpha by the ubiquitin-proteasome pathway. J Biol Chem 1999;274:6519-25. (Pubitemid 29111068)
9. Maxwell PH, Wiesener MS, Chang GW, et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 1999;399:271-5. (Pubitemid 29246458)
10. Ohh M, Park CW, Ivan M, et al. Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel- Lindau protein. Nat Cell Biol 2000;2:423-7.
11. 2 sensing. Science 2001;292:464-8.
12. 2-regulated prolyl hydroxylation. Science 2001;292:468-72.
13. Yu F, White SB, Zhao Q, Lee FS. HIF-1alpha binding to VHL is regulated by stimulus-sensitive proline hydroxylation. Proc Natl Acad Sci U S A 2001;98:9630-5. (Pubitemid 32769354)
14. Erler JT, Bennewith KL, Nicolau M, et al. Lysyl oxidase is essential for hypoxia-induced metastasis. Nature 2006;440:1222-6.
15. Kaelin WG Jr, Ratcliffe PJ. Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. Mol Cell 2008;30: 393-402. (Pubitemid 351681994)
16. Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. Nat Med 2004;10:789-99. (Pubitemid 39070849)
17. Bristow RG, Hill RP. Hypoxia and metabolism. Hypoxia, DNA repair and genetic instability. Nat Rev Cancer 2008;8:180-92.
18. Huang LE, Bindra RS, Glazer PM, Harris AL. Hypoxia-induced genetic instability-a calculated mechanism underlying tumor progression. J Mol Med 2007;85:139-48. (Pubitemid 46188219)
19. Koshiji M, To KK, Hammer S, et al. HIF-1alpha induces genetic instability by transcriptionally downregulating MutSalpha expression. Mol Cell 2005;17:793-803. (Pubitemid 40386941)
20. To KK, Sedelnikova OA, Samons M, Bonner WM, Huang LE. The phosphorylation status of PAS-B distinguishes HIF-1alpha from HIF- 2alpha in NBS1 repression. EMBO J 2006;25:4784-94. (Pubitemid 44607024)
21. Huang LE. Carrot and stick: HIF-alpha engages c-Myc in hypoxic adaptation. Cell Death Differ 2008;15:672-7. (Pubitemid 351405071)
22. Kageyama Y, Koshiji M, To KK, Tian YM, Ratcliffe PJ, Huang LE. Leu- 574 of human HIF-1alpha is a molecular determinant of prolyl hydroxylation. FASEB J 2004;18:1028-30. (Pubitemid 39561514)
23. Koshiji M, Kageyama Y, Pete EA, Horikawa I, Barrett JC, Huang LE. HIF-1alpha induces cell cycle arrest by functionally counteracting Myc. EMBO J 2004;23:1949-56. (Pubitemid 38902073)
24. Land SC, Tee AR. Hypoxia-inducible factor 1alpha is regulated by the mammalian target of rapamycin (mTOR) via an mTOR signaling motif. J Biol Chem 2007;282:20534-43. (Pubitemid 47100043)
25. Gu J, Milligan J, Huang LE. Molecular mechanism of hypoxia-inducible factor 1alpha-p300 interaction. A leucine-rich interface regulated by a single cysteine. J Biol Chem 2001;276:3550-4.
26. Yoo YG, Kong G, Lee MO. Metastasis-associated protein 1 enhances stability of hypoxia-inducible factor-1alpha protein by recruiting histone deacetylase 1. EMBO J 2006;25:1231-41.
27. Zhang H, Gao P, Fukuda R, et al. HIF-1 inhibits mitochondrial biogenesis and cellular respiration in VHL-deficient renal cell carcinoma by repression of C-MYC activity. Cancer Cell 2007;11:407-20. (Pubitemid 46670080)
28. Kaidi A, Williams AC, Paraskeva C. Interaction between beta-catenin and HIF-1 promotes cellular adaptation to hypoxia. Nat Cell Biol 2007;9:210-7. (Pubitemid 46420864)
29. Durkin SG, Glover TW. Chromosome fragile sites. Annu Rev Genet 2007;41:169-92.
30. Hinohara S, Satake N, Sekine K, Kaneko Y. Abnormalities of the FHIT transcripts in osteosarcoma and Ewing sarcoma. Jpn J Cancer Res 1998;89:887-94. (Pubitemid 28486813)
31. Del Mare S, Salah Z, Aqeilan RI. WWOX: its genomics, partners, and functions. J Cell Biochem 2009;108:737-45.
32. Peinado H, Olmeda D, Cano A. Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype?Nat Rev Cancer 2007;7:415-28.
33. Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2002;2:442-54.
34. Esteban MA, Tran MG, Harten SK, et al. Regulation of E-cadherin expression by VHL and hypoxia-inducible factor. Cancer Res 2006;66:3567-75.
35. Yang MH, Wu MZ, Chiou SH, et al. Direct regulation of TWIST by HIF- 1alpha promotes metastasis. Nat Cell Biol 2008;10:295-305.
36. Krishnamachary B, Zagzag D, Nagasawa H, et al. Hypoxia-inducible factor-1-dependent repression of E-cadherin in von Hippel-Lindau tumor suppressor-null renal cell carcinoma mediated by TCF3, ZFHX1A, and ZFHX1B. Cancer Res 2006;66:2725-31.
37. Evans AJ, Russell RC, Roche O, et al. VHL promotes E2 box-dependent E-cadherin transcription by HIF-mediated regulation of SIP1 and Snail. Mol Cell Biol 2007;27:157-69. (Pubitemid 46013241)
38. Comijn J, Berx G, Vermassen P, et al. The two-handed E box binding zinc finger protein SIP1 downregulates E-cadherin and induces invasion. Mol Cell 2001;7:1267-78. (Pubitemid 32607360)
39. Gordan JD, Bertout JA, Hu CJ, Diehl JA, Simon MC. HIF-2alpha promotes hypoxic cell proliferation by enhancing c-myc transcriptional activity. Cancer Cell 2007;11:335-47. (Pubitemid 46518312)
40. Okuyama H, Endo H, Akashika T, Kato K, Inoue M. Downregulation of c-MYC protein levels contributes to cancer cell survival under dual deficiency of oxygen and glucose. Cancer Res 2010;70: 10213-23.
41. Kim JW, Gao P, Liu YC, Semenza GL, Dang CV. HIF-1 and dysregulated c-Myc cooperatively induces VEGF and metabolic switches, HK2 and PDK1. Mol Cell Biol 2007;27:7381-93.
42. Qing G, Skuli N, Mayes PA, et al. Combinatorial regulation of neuroblastoma tumor progression by N-Myc and hypoxia inducible factor (HIF)-1alpha. Cancer Res 2010;70:10351-61.
43. Gordan JD, Lal P, Dondeti VR, et al. HIF-alpha effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma. Cancer Cell 2008;14:435-46.
44. Raval RR, Lau KW, Tran MG, et al. Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma. Mol Cell Biol 2005;25:5675-86. (Pubitemid 40853601)
45. Kondo K, Klco J, Nakamura E, Lechpammer M, Kaelin WG. Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. Cancer Cell 2002;1:237-46. (Pubitemid 41039148)
46. Holmquist-Mengelbier L, Fredlund E, Löfstedt T, et al. Recruitment of HIF-1alpha and HIF-2alpha to common target genes is differentially regulated in neuroblastoma: HIF-2alpha promotes an aggressive phenotype. Cancer Cell 2006;10:413-23. (Pubitemid 44693470)
47. Qing G, Simon MC. Hypoxia inducible factor-2alpha: a critical mediator of aggressive tumor phenotypes. Curr Opin Genet Dev 2009;19:60-6.
48. Lei L, Mason S, Liu D, et al. Hypoxia-inducible factor-dependent degeneration, failure, and malignant transformation of the heart in the absence of the von Hippel-Lindau protein. Mol Cell Biol 2008;28:3790-803. (Pubitemid 351732913)
49. Gregory PA, Bert AG, Paterson EL, et al. The miR-200 family and miR- 205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol 2008;10:593-601. (Pubitemid 351627379)
50. Park SM, Gaur AB, Lengyel E, Peter ME. The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev 2008;22: 894-907. (Pubitemid 351482843)